Influence of gender on the effect-site concentration of remifentanil for the the conventional laryngeal mask airway insertion during target-controlled infusion of propofol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000151

Enrollment

100

Registered

2011-07-26

Start date

2010-06-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Using Target controlled infusion (TCI)(Orchestra®, Fresenius Vial, France), propofol was infused at the target effect-site concentration of 3.5 ug.ml-1. At the same time, the first pa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: After obtaining the approval of institutional ethics committe and written informed consent, patients aged 18-60 yr of ASA physical status I or II scheduled to undergo elective monior surgery requiring general anesthesia.

Exclusion criteria

Exclusion criteria: Patients with a potentially difficult airway (Mallampati classification III or IV. Cervical spine disease, or a mouth opening of < 2.5 cm), signs of upper respiratory infection, history of reactive airway disease or gastro-esophageal reflux, and a history of allergic reaction to the anesthesia drugs (propofol).

Design outcomes

Primary

Measure	Time frame
EC50 and EC95 of remifentanil for successful LMA insertion for men and women	—

Countries

Korea, Republic of

Contacts

Public ContactSoo Hwan Kim

Hallym University Medical Center-Kangnam

Outcome results